Unlike traditional non-selective COX inhibitors, CAG can precisely inhibit the NF-κB/COX-2/PGE2 inflammatory axis of NF- κB/COX-2/PGE2, reducing the release of prostaglandin E2 (PGE2), thus inhibiting tumor-related inflammation and proliferation, while avoiding gastrointestinal side effects caused by inhibition of COX-1. This evidence concerns the gene PTGS2 and neoplasm.